Pharmaceuticals (Feb 2023)

Cyclotron-Based Production of <sup>67</sup>Cu for Radionuclide Theranostics via the <sup>70</sup>Zn(p,α)<sup>67</sup>Cu Reaction

  • Santiago Andrés Brühlmann,
  • Martin Walther,
  • Martin Kreller,
  • Falco Reissig,
  • Hans-Jürgen Pietzsch,
  • Torsten Kniess,
  • Klaus Kopka

DOI
https://doi.org/10.3390/ph16020314
Journal volume & issue
Vol. 16, no. 2
p. 314

Abstract

Read online

Theranostic matched pairs of radionuclides have aroused interest during the last couple of years, and in that sense, copper is one element that has a lot to offer, and although 61Cu and 64Cu are slowly being established as diagnostic radionuclides for PET, the availability of the therapeutic counterpart 67Cu plays a key role for further radiopharmaceutical development in the future. Until now, the 67Cu shortage has not been solved; however, different production routes are being explored. This project aims at the production of no-carrier-added 67Cu with high radionuclidic purity with a medical 30MeV compact cyclotron via the 70Zn(p,α)67Cu reaction. With this purpose, proton irradiation of electrodeposited 70Zn targets was performed followed by two-step radiochemical separation based on solid-phase extraction. Activities of up to 600MBq 67Cu at end of bombardment, with radionuclidic purities over 99.5% and apparent molar activities of up to 80MBq/nmol, were quantified.

Keywords